therapy

[키워드] 1:1 24 hour 28-day mortality activated acute respiratory distress syndrome Administered Admission adverse effect age albumin allergic allocation concealment Anticoagulant apheresis approval approved assessment Basel block size C-reactive protein category changes in city Coagulopathy Control COVID-19 COVID-19 disease criteria Cytokine release syndrome D-dimer defined disease dissemination drug eight element Enrollment evaluate evaluated ferritin fibrinogen first dose FIVE food function group ICU ICU admission ill patient Improving Inc. Inflammatory ingredient intensive care intensive care unit International Intervention intervention group intubation IRB ISRCTN KDIGO King Kingdom Laboratory lack lactate dehydrogenase life threatening life-threatening Life-threatening COVID-19 marker measure Mild Ministry of Health Multicenter trial Multisystem organ failure National negative RT-PCR normalized number objective occur on mechanical ventilation Open-label outcome Palliative care participant Participants Patient patients performed pilot study plasma primary site Prothrombin time protocol Qiagen randomization randomize Randomized Randomized controlled trial randomized trial Real-time PCR receive receiving recommendations recruit reduce replaced Roche RT-PCR RT-PCR kit Safety Sample size SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection Saudi Arabia secondary serum Seven sodium SOFA status Stratification Study protocol supportive care Switzerland System Therapeutic plasma exchange therapy TPE treatment for COVID-19 tumor necrosis factor-alpha USA Volume website
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter